Andorra has an excellent health system, with access to state-of-the-art facilities and equipment, as well as world-class medical and pharmacology specialists. The clinical research regulations in Andorra are mature and meet the high-quality standards of any other European country. Data generated in Andorra can be used to support not only EMA, but also IND and NDA regulatory filings for the USA FDA.
Andorra has a relatively small but concentrated population which allows highly efficient clinical trial advertising campaigns at a very reasonable cost. Due to the seasonal nature of Andorra's economy (winter and summer season), the pool of candidates available for early-stage trials or bioequivalence studies, such as healthy volunteers, is significant. Medical facilities in Andorra are easily accessible by foot or public transportation.
The costs of conducting a trial in Andorra are generally lower than in other countries such as the UK, Germany, or the US. Not only are the costs lower, but the results obtained are also of exceptional quality. Furthermore, the clinical trial approval processes in Andorra are centralized and streamlined, which effectively reduces the clinical trial start-up time. It is also worth noting that an IND is not required to obtain clinical trial approval in Andorra.
We primarily focus on conducting single-center early-stage clinical trials (Phase 1) in healthy volunteers, whether inpatient or outpatient and bioequivalence studies.
As an Andorra based CRO, we can also identify and manage local investigators and sites to participate in multi-center clinical development programs for drugs or medical devices at any stage of development.
We offer a range of services, including protocol writing, regulatory services, and clinical operations. Our clinical operations services include site management, monitoring, and trial master file management.
We also offer data management services, including designing and deploying modern electronic data capture systems, as well as biostatistics services via experienced vendors.